2024
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Schoenfeld A, Lee S, de Speville B, Gettinger S, Hafliger S, Sukari A, Papa S, Rodriguez-Moreno J, Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller E, Gontcharova V, He K. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery 2024, 14: 1389-1402. PMID: 38563600, PMCID: PMC11294887, DOI: 10.1158/2159-8290.cd-23-1334.Peer-Reviewed Original ResearchMetastatic non-small cell lung cancerAdverse eventsResistance to immune checkpoint inhibitorsPD-L1-negative tumorsPhase 2 multicenter studyLow tumor mutational burdenTreatment-emergent adverse eventsNon-small cell lung cancerTime of data cutoffRefractory to prior therapyPD-L1-negativeImmune checkpoint inhibitorsResistance to immunotherapyTumor mutational burdenCell lung cancerMultiple organ failurePotential treatment optionCheckpoint inhibitorsPrior therapyData cutoffPatient diedSystemic therapyMutational burdenSTK11 mutationsCardiac failure
2021
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
Schoenfeld A, Lee S, Paz-Ares L, Doger B, Gettinger S, Haefliger S, Orcurto A, Sukari A, Papa S, Rodriguez Moreno J, Finckenstein F, Jagasia M, Fiaz R, Sulur G, Chen G, Gontcharova V, He K. 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). 2021, a486-a487. DOI: 10.1136/jitc-2021-sitc2021.458.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsAdvanced non-small cell lung cancerDurable responsesPrior linesSystemic therapyMetastatic non-small cell lung cancerFirst-line immune checkpoint inhibitorsPrior immune checkpoint inhibitorsT cell receptor repertoireExpected safety profileExploratory biomarker analysisPhase 2 multicenterObjective response rateOpen-label studyComplete metabolic responsePD-L1 expressionMajority of patientsCell lung cancerTCR repertoire analysisOncogene-directed therapyBest percentage changeInstitutional review boardWarrants further investigationInformed consent form
2020
Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N, Gettinger S. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective. The Cancer Journal 2020, 26: 144-148. PMID: 32205539, DOI: 10.1097/ppo.0000000000000439.Peer-Reviewed Original ResearchConceptsAggressive local therapySubset of patientsLocal therapyOligometastatic diseaseCancer patientsNon-small cell lung cancer patientsOligometastatic colorectal cancer (CRC) patientsCell lung cancer patientsLong-term disease remissionStereotactic body radiation therapyLimited nodal involvementMedical oncology perspectiveDefinitive local therapyColorectal cancer patientsSolid tumor patientsLung cancer patientsSolid tumor malignanciesBody radiation therapyDisease remissionOligometastatic statePrimary therapyNodal involvementOverall survivalSystemic therapyMetastatic sites
2019
O1-4-2 [Encore] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L
Yang J, Kim H, Ahn M, Han J, Hochmair M, Lee K, Delmonte A, Campelo M, Kim D, Felip E, Califano R, Spira A, Gettinger S, Tiseo M, Haney J, Kerstein D, Popat S, Camidge D. O1-4-2 [Encore] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals Of Oncology 2019, 30: vi83. DOI: 10.1093/annonc/mdz339.006.Peer-Reviewed Original ResearchIntracranial ORRInterim analysisPFS eventsBlinded independent review committeeAsymptomatic CNS metastasesBaseline brain metastasesMost common gradeSecondary efficacy endpointsFirst interim analysisIndependent review committeeCNS metastasisMedian iPFSMedian PFSPrior chemotherapyAdvanced diseaseEfficacy endpointPrimary endpointBrain metastasesData cutoffSystemic therapyALK-TKIMedian ageMulticenter studyCommon gradeCrizotinibComparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV diseaseA phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.
Chesney J, Lutzky J, Thomas S, Nieva J, Munoz Couselo E, Martin-Liberal J, Rodriguez-Moreno J, Cacovean A, Li H, Fardis M, Gettinger S. A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors. Journal Of Clinical Oncology 2019, 37: tps2648-tps2648. DOI: 10.1200/jco.2019.37.15_suppl.tps2648.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPrior immune checkpoint inhibitorsObjective response rateTIL therapyAdoptive cell therapySystemic therapyCohort 1Cohort 3RECIST 1.1Metastatic melanomaNeck cancerPhase 2 multicenterPrior systemic therapyDurable complete responseOpen-label studyPhase II studyMetastatic melanoma patientsCo-primary endpointsHigh mutational burdenAutologous tumorECOG PSMeasurable diseaseAcceptable toxicityCheckpoint inhibitorsImmunogenic tumorsBenefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustment
2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal Of Cancer 2018, 101: 201-209. PMID: 30077125, DOI: 10.1016/j.ejca.2018.06.031.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsBaseline PD-L1 expressionObjective response ratePD-L1 expressionPD-L1Immune cellsGrade treatment-related adverse eventsSurvival rateCell lung cancer cohortLong-term clinical benefitTumor-infiltrating immune cellsTumor cellsPhase IPrevious systemic therapySingle-agent atezolizumabCell lung cancerExploratory subgroup analysisLung cancer cohortAtezolizumab monotherapyAdverse eventsDurable responsesMedian durationSystemic therapyAnticancer immunityPD-1
2016
Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
Alomari AK, Cohen J, Vortmeyer AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL. Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. Cancer Immunology Research 2016, 4: 481-487. PMID: 26994250, DOI: 10.1158/2326-6066.cir-15-0238.Peer-Reviewed Original ResearchConceptsStereotactic radiosurgeryBrain metastasesInitiation of immunotherapyPD-1 mAbImmune-modulating therapyModalities of treatmentRadiologic progressionSurgical resectionSystemic therapyDeath-1Radiologic findingsMetastatic malignancyReactive astrocytosisPathologic examinationTreatment regimensHistopathologic examinationWall infiltrationT lymphocytesPatientsTumor progressionMonoclonal antibodiesBiologic interactionsRadiation-induced changesImmunotherapyMalignancyCeritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer
Qian J, Yu J, Gettinger S, Chiang V. Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. Cancer Treatment And Research Communications 2016, 6: 17-19. DOI: 10.1016/j.ctrc.2016.02.002.Peer-Reviewed Original ResearchNon-small cell lung cancerAnaplastic lymphoma kinaseWhole-brain radiation therapySymptomatic brain metastasesBrain radiation therapyCell lung cancerBrain metastasesStereotactic radiosurgerySystemic therapyLung cancerRadiation therapyActive small-molecule tyrosine kinase inhibitorLarge symptomatic brain metastasisNext-generation ALK inhibitorsSmall molecule tyrosine kinase inhibitorsYear old Caucasian femaleMolecule tyrosine kinase inhibitorsGeneration ALK inhibitorsALK inhibitor crizotinibOld Caucasian femaleKey driver mutationsTyrosine kinase inhibitorsLocal therapyInhibitor crizotinibALK inhibitors
2010
Management of Patients with Advanced Non-Small Cell Lung Cancer
Triano LR, Deshpande H, Gettinger SN. Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 2010, 70: 167-179. PMID: 20108990, DOI: 10.2165/11532200-000000000-00000.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorGrowth factor receptorOverall survivalLung cancerThird-line treatmentFirst-line chemotherapyFactor receptorManagement of patientsVascular endothelial growth factorQuality of lifeEndothelial growth factorMedian survivalSystemic therapyRandomized trialsTraditional chemotherapySmall molecule inhibitorsFDA approvalUS FDAChemotherapyKey mediatorGrowth factorAdditional agents